Teoh by a Human Antibody The Structural Basis for Serotype-Specific Neutralization of Dengue Virus

implications for the design and evaluation of vaccines against dengue. context for understanding the nature of durable, serotype-specific immunity to dengue infection and thus have therapeutic candidate for treating dengue serotype 1 infection. These findings also provide a structural and molecular This human antibody represents a new . results in increased survival in a mouse model of dengue virus infection of this antibody is linked principally to a blockade of virus binding to target host cells. Treatment with this antibody two adjacent viral envelope proteins and identify the amino acids that comprise the binding site. The antiviral activity no binding or neutralizing activity for serotypes 2, 3, and 4. The authors demonstrate that the antibody binds across antibody induced by natural dengue infection. This antibody is specific for dengue virus serotype 1 and shows little or characterize a neutralizing human monoclonal et al. little is known about their specificity or mode of action. Now, Teoh but only short-term immunity against the other serotypes. Immunity is mediated by serotype-specific antibodies, but distinct serotypes, and infection is thought to elicit lifelong immunity to the infecting serotype in patients who recover Thus, there is an urgent need for new treatment options for this disease. Dengue virus consists of four related but are no approved vaccines or antiviral therapies for dengue, and current treatment is restricted to fluid replacement. mosquito. Infection can be asymptomatic, cause a self-limiting fever, or result in potentially fatal hemorrhage. There Dengue virus is a major mosquito-borne viral pathogen that is transmitted through the bite of an infected Defeating Dengue